Clinical trial

Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer

NCT00473746

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-06-01

PhasePHASE1 / PHASE2

Study timeline

Study start (unknown)2006-06-01Date precision: month

Registry last updated2014-04-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Neoplasmsunresolved

Interventions

Abiraterone acetateDRUG · verified · RxNorm: abiraterone acetate

prednisone/prednisolone or dexamethasoneDRUG

Sponsors & collaborators

Janssen Research & Development, LLClead sponsor

Mapped research locations

HoustonTexas, United States1 BostonMassachusetts, United States1 San FranciscoCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00473746 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.